| abstract |
Disclosed herein is a class of pyrazolo[1,5-a]pyrimidine compounds of formula (III), wherein Q is selected from the group consisting of -S(O2)NR6R7-, -C(O)NR6R7- and -C(O)OR7-; and the substituents for all other variables shown in formula (III) are as defined in the specification. These compounds are suitable as inhibitors of cyclin dependent kinases (CDKs). Also disclosed are methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and their suitability for the treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions. |